# Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure

> **NCT04420741** · PHASE2 · COMPLETED · sponsor: **Pär Johansson** · enrollment: 80 (actual)

## Conditions studied

- COVID-19
- Respiratory Failure

## Interventions

- **DRUG:** Iloprost
- **DRUG:** Isotonic saline

## Key facts

- **NCT ID:** NCT04420741
- **Lead sponsor:** Pär Johansson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2021-02-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04420741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04420741, "Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04420741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*